What the research found

Researchers identified a mechanism linking stem cell aging to chronic inflammation in mice. The culprit is reduced activity of SIRT3, a mitochondrial enzyme that normally keeps hematopoietic stem cells (the bone marrow cells that produce immune cells) in check. As SIRT3 declines with age, these stem cells become "overtrained"—they generate myeloid immune cells that trigger a persistent inflammatory state rather than responding appropriately to genuine threats.

When the team experimentally restored SIRT3 function in aging mice's stem cells, the animals showed reduced systemic inflammation and improved function in tissues far removed from the bone marrow—including better cognitive performance and physical mobility. This suggests the problem isn't localized to immune tissue, but that dysregulated stem cells broadcast inflammatory signals throughout the body.

Why it matters for you

If this translates to humans, it reframes how you might think about chronic inflammation on your biomarker panels. Many MyKine users track inflammatory markers like CRP, IL-6, or TNF-α as aging risk factors. This work suggests that interventions targeting stem cell health and mitochondrial function—not just downstream cytokines—could address root causes rather than symptoms.

For your protocols, this hints at why interventions that support mitochondrial health might have outsized anti-inflammatory effects. Whether through NAD+ boosters, mitochondrial-supporting compounds, or strategies that improve metabolic flexibility, the implication is that stem cell resilience could be a lever worth optimizing. Better stem cell function may explain some of the cognitive and mobility benefits people report from comprehensive longevity protocols, beyond what you'd predict from any single intervention.

It also suggests that tracking functional outcomes—cognition, strength, mobility—alongside blood biomarkers captures something real about systemic aging, not just subjective perception.

Caveats

• Mouse model: Findings are from rodent studies; human translation is unproven
• SIRT3 specificity: It's unclear which SIRT3-dependent pathways matter most, or whether boosting SIRT3 alone would replicate the tissue-wide benefits
• Mechanism in humans: Humans may have different age-related SIRT3 regulation or compensatory pathways
• Therapeutic timeline: No data on whether restoring SIRT3 function in already-aged organisms reverses decline, or only slows future decline